Last $73.10 USD
Change Today 0.00 / 0.00%
Volume 0.0
AZNCF On Other Exchanges
Symbol
Exchange
Xetra
London
OTC US
Mexico
Berlin
As of 8:10 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Open
$73.10
Previous Close
$73.10
Day High
$73.10
Day Low
$73.10
52 Week High
05/1/14 - $81.70
52 Week Low
09/10/13 - $48.85
Market Cap
92.3B
Average Volume 10 Days
156.1
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
$3.11
Dividend Yield
4.26%
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; and Qiagen N.V. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZNCF) Key Developments

AstraZeneca PLC Recommends First Interim Dividend, Payable on 15 September 2014

AstraZeneca PLC announced that its board has recommended a first interim dividend of $0.90 (53.1 pence, SEK 6.20). The amount of the dividend reflects the Board's aim of setting the first interim dividend at around a third of the prior year dividend, which last year was $2.80. The record date for the first interim dividend payable on 15 September 2014 is 15 August 2014. Shares will trade ex-dividend from 13 August 2014.

Astrazeneca Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Raises Earnings Guidance for the Full Year of 2014

Astrazeneca announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the second quarter, on reported basis, revenue was $6,454 million. Operating profit was $1,109 million. Profit before tax was $866 million. Profit after tax was $797 million. Net profit was $796 million. Earnings per share were $0.63. On core basis, revenue was $6,454 million against $6,232 million for the same period in the last year. Operating profit was $2,031 million against $2,056 million for the same period in the last year. Profit before tax was $1,890 million against $1,942 million for the same period in the last year. Profit after tax was $1,643 million against $1,510 million for the same period in the last year. Net profit was $1,642 million against $1,502 million for the same period in the last year. Earnings per share were $1.30 against $1.20 for the same period in the last year. For the six months, on reported basis, revenue was $12,870 million against $12,617 million for the same period in the last year. Operating profit was $1,945 million against $2,597 million for the same period in the last year. Profit before tax was $1,504 million against $2,390 million for the same period in the last year. Profit for the period was $1,303 million against $1,843 million for the same period in the last year. Profit attributable to owners of the parent was $1,300 million against $1,655 million for the same period in the last year. Diluted earnings per $0.25 Ordinary Share was $1.03 against $1.47 for the same period in the last year. Cash generated from operations was $4,274 million against $4,831 million for the same period in the last year. Purchase of property, plant and equipment was $378 million against $231 million for the same period in the last year. Net debt at 30 June 2014 was $3,959 million for the same period in the last year. On core basis, revenue was $12,870 million against $12,617 million for the same period in the last year. Operating profit was $3,893 million against $4,380 million for the same period in the last year. Profit before tax was $3,716 million against $4,173 million for the same period in the last year. Profit attributable to owners of the parent was $3,113 million against $3,256 million for the same period in the last year. Earnings per share were $2.47 against $2.61 for the same period in the last year. The company raised earnings guidance for the full year of 2014. The company expects 2014 revenues to be in line with the prior year. That was an upgrade from previous guidance for low-to-mid single digit percentage decline. Earnings per share (EPS) were expected to fall in low double-digits at CER, an update on its previous guidance of a percentage decrease in the teens.

AstraZeneca and Kyowa Hakko Kirin Partner on Immuno-Oncology Clinical Study

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours. The study will evaluate AstraZeneca's anti-PD-L1 antibody, MEDI4736, in combination with Kyowa Hakko Kirin's anti-CCR4 antibody, mogamulizumab, and AstraZeneca's anti-CTLA-4 antibody tremelimumab, in combination with mogamulizumab. MEDI4736, tremelimumab, and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which use the body's own immune system to help fight cancer. MEDI4736 and tremelimumab block the signals that help tumours avoid detection by the immune system, while mogamulizumab suppresses some of the immune cells that shield the tumour from the immune system. Under the terms of the agreement, AstraZeneca and Kyowa Hakko Kirin will co-fund the study, which will be conducted by Kyowa Hakko Kirin. The Phase I part of the study is expected to establish a recommended dose regimen and Phase Ib will assess the safety and efficacy of the two combinations. Results from these studies will determine the future clinical development of the combinations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $73.10 USD 0.00

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $52.23 USD -0.11
Bayer AG €96.05 EUR -2.35
Biogen Idec Inc $331.88 USD -2.51
Bristol-Myers Squibb Co $50.24 USD -0.38
Novo Nordisk A/S kr251.20 DKK -6.70
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 45.3x
Price/Sales 3.6x
Price/Book 4.3x
Price/Cash Flow 45.5x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.